ARRIVENT BIOPHARMA INC (AVBP) — insider trading
Health Care · NASDAQ
ARRIVENT BIOPHARMA INC (AVBP) has 17 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 17 (latest 2026-06-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Nolet Chris | Director | Grant / award / vesting (derivative) | 13,562 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Hohneker John | Director | Grant / award / vesting (derivative) | 13,562 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Peterson Kristine | Director | Grant / award / vesting (derivative) | 13,562 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Parsey Merdad | Director | Grant / award / vesting (derivative) | 13,562 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Kastenmayer James Paul | Officer (General Counsel) | Grant / award / vesting (derivative) | 130,000 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Yao Zhengbin | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 550,000 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Kung Winston | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 140,000 | $0.00 | $0 | Form 4 |
| 2026-02-02 | Lutzker Stuart | Director, Officer (President of R&D) | Grant / award / vesting (derivative) | 150,000 | $0.00 | $0 | Form 4 |
| 2026-02-02 | LaChapelle Robin | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 130,000 | $0.00 | $0 | Form 4 |
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD.; HHLR ADVISORS, LTD. | 10% owner | Open-market sale | 555,555 | $23.37 | $12.98M | Form 4 |
| 2025-07-11 | LaChapelle Robin | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 6,503 | $0.00 | $0 | Form 4 |
| 2025-07-11 | LaChapelle Robin | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,600 | $0.00 | $0 | Form 4 |
| 2025-07-11 | LaChapelle Robin | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,050 | $0.00 | $0 | Form 4 |
| 2025-07-11 | LaChapelle Robin | Officer (Chief Operating Officer) | Option exercise / conversion | 6,503 | $2.28 | $14.8K | Form 4 |
| 2025-07-11 | LaChapelle Robin | Officer (Chief Operating Officer) | Option exercise / conversion | 2,600 | $2.28 | $5.9K | Form 4 |
| 2025-07-11 | LaChapelle Robin | Officer (Chief Operating Officer) | Option exercise / conversion | 2,050 | $2.28 | $4.7K | Form 4 |
| 2025-06-18 | Parsey Merdad | Director | Grant / award / vesting (derivative) | 15,502 | $0.00 | $0 | Form 4 |
Ask the chat about AVBP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARRIVENT BIOPHARMA INC (AVBP).
Last updated 2026-06-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.